Table 1.
Curcumin and its analogues with ER stress-mediated anticancer activity.
| Compound | Tumor Type/Cell Line | ER Stress Signaling | Reference |
|---|---|---|---|
| Curcumin (Curcuma longa) |
Human prostate cancer PC3 |
↑ IRE1α; BiP; PDI; calreticulin | [59] |
| Curcumin (Curcuma longa) |
Murine Myeloma WEHI-3 |
↑ ATF6; CHOP; IRE1α; caspase-12 | [60] |
| Curcumin + sildenafil (Curcuma longa) |
Human gastric, colon, liver cancer HC116; HT29; HEPG2 |
↑ pEIF2α; CHOP | [61] |
| Curcumin + irinotecan (Curcuma longa) |
Human colorectal cancer HT29; LoVo |
↑ CHOP; PDI; BiP | [62] |
| Bisdemethoxycurcumin | Human lung cancer NCI H460 |
↑ BiP; IRE 1(α and β); CHOP; ATF6(α and β); caspase-4 | [63] |
| Demetoxycurcumin | Human lung cancer NCI H460 |
↑ BiP; IRE 1β; CHOP; ATF6(α and β); caspase-4 | [64] |
| B63 analogue of curcumin |
Human colon cancer SW620 |
↑ ER stress markers | [65] |
| B19 analogue of curcumin |
Human ovarian cancer A2780; CP70 |
↑ ROS; p-PERK; pEIF2α; CHOP | [66] |
| WZ35 analogue of curcumin |
Human lung cancer HI975 |
↑ pEIF2α; ATF4; CHOP | [67] |
| MTH-3 analogue of curcumin |
Human breast cancer MDA-MB-231 |
↑ CHOP; ERO1; PDI; PERK; calnexin ↓BiP | [68] |
↑-increasing concentration; ↓-decreasing concentration.